-

Kashiv Biosciences Expands Leadership Team with New Chief Financial Officer and Chief Legal Officer

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a global vertically integrated biopharmaceutical company, announced the appointment of Mandar Borkar as Global Chief Financial Officer (CFO) and Ross Oehler as Global Chief Legal Officer (CLO).

“We are pleased to welcome Mandar Borkar and Ross Oehler to the management team,” said Chirag and Chintu Patel, Co-Founders of Kashiv BioSciences, “With two approved products on the market and a rapidly advancing pipeline, we are confident their expertise will play a pivotal role in advancing Kashiv to new heights.”

Mandar Borkar brings over 25 years of experience in the pharmaceutical industry managing complex financial structures, leading M&A and finance transformation, and governing global finance teams. Mr. Borkar’s career includes roles at Mahindra & Mahindra, Parke Davis, Lupin, and Watson Pharma. As CFO of Indoco Remedies, he optimized operational efficiency and positioned the company for long-term financial growth. Most recently, Mr. Borkar led Abbott’s Financial Controlling Function, ensured Financial Reporting and Compliance, and drove advancements in finance operations. He is a member of the Institute of Chartered Accountants of India and Institute of Cost and Management Accountants of India. Mr. Borkar holds a B Com from Mumbai University.

Ross Oehler brings over 30 years of biopharmaceutical experience from Sanofi-Aventis, Cephalon Inc., and Johnson Matthey, Inc., handling complex legal matters. Mr. Oehler heads the global Legal and IP groups, providing support on matters including IP, litigation, corporate governance, regulatory policy, compliance, and commercial transactions. Mr. Oehler has been involved in numerous IP and commercial disputes in the US Federal Courts, International Trade Commission, and post-grant review proceedings in US and European Patent Offices. He is a member of the Association of Corporate Counsel, Association of Corporate Patent Counsel, and served on the Board of Directors of the IP Owners Association. Mr. Oehler holds a JD from New York Law School and Bachelor’s degree in Biology from Gettysburg College.

About Kashiv:

Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. Kashiv BioSciences, LLC in the United States, and its subsidiaries in India (together “Kashiv BioSciences”) operate together with robust infrastructure and highly skilled teams that provide global R&D, clinical, manufacturing, regulatory, and IP capabilities. We believe our people, partners, and shared purpose fuel our work to advance patient care and access to important medicines.

Kashiv BioSciences, LLC


Release Versions

More News From Kashiv BioSciences, LLC

Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC, a fully-integrated biopharmaceutical company, announced that they have submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA), and the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA), for ADL-018, a proposed biosimilar to XOLAIR® (omalizumab). The submissions are intended to seek approval in the United States and the European Economic Area, respectively....

Kashiv BioSciences and JAMP Pharma Corporation Announce the Launch of PEXEGRA® and FILRA® Biosimilars in Canada

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC today announced the commercial launch of PEXEGRA®, a biosimilar referencing Neulasta®, and FILRA®, a biosimilar referencing Neupogen®, in the Canadian market. Both biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation. PEXEGRA® (6 mg/0.6 mL pre-filled syringe) and FILRA® (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils which are a type of w...

Kashiv BioSciences and CRISTÁLIA Enter into Licensing and Supply Agreement for Omalizumab Biosimilar (ADL-018) in Latin America

PISCATAWAY, N.J.--(BUSINESS WIRE)--Kashiv BioSciences, LLC (“Kashiv” or the “Company”) today announced that it has entered into a licensing and supply agreement with CRISTÁLIA, one of the leading pharmaceutical companies in Brazil, for the commercialization of ADL-018 / bOmalizumab, a proposed biosimilar to Xolair®, in Latin America (LATAM). In 2024, IQVIA recorded approximately $5.0 billion in global sales, with approximately $140 million contributed by the LATAM region. Under the terms of the...
Back to Newsroom